TrialJournal of immunology research2015

Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.

Sang Jin Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.